Sophia Abene

At MAD-ID, Jose Alexander, MD, reports 98% susceptibility in ESBL E coli and 76% in K pneumoniae, underscoring the need for species-specific testing.

At MAD-ID 2025, Tiffany Lee, PharmD, presents multi-center findings showing no increase in AKI with higher initial dosing.

At MAD-ID 2025, William R Mikesell, PharmD, presented data showing 20% vs 16% treatment failure rates in doxycycline and minocycline groups.

Christina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.

At MAD-ID, Dianne Nguyen, MD, shares Phase 3 data showing consistent tolerability of the microbiome therapy across high-risk patient populations

At MAD-ID, Marc Scheetz, PharmD, discusses how PK/PD modeling and AUC-based strategies offer safer, more precise antibiotic therapy.

Logan Brock, PharmD, presents data at MAD-ID, showing limited diagnostic yield from routine fungal cultures and delayed results compared with standard methods.

At MAD-ID 2025, Kimberly Leuthner, PharmD, FIDSA, highlights the need for larger prospective studies amid limited current evidence.

At MAD-ID 2025, Jiye Park, PharmD, presents findings showing once-daily dosing is effective, with no added benefit from extended vancomycin use after antibiotics.

At MAD-ID 2025, Dakota Rorie, PharmD, highlights cost and access barriers to uptake of preferred CDI therapy.

At MAD-ID 2025, Rachel M. Kenney, PharmD, discusses treatment shifts, microbiome innovations, and pharmacists' roles in optimizing outcomes.

Timmy Do, PharmD, BCIDP, BCPS, presents case series at MAD-ID 2025 on investigational therapies following tecovirimat failure.

At MAD-ID 2025, Cadhan McFadden presents data from a multidisciplinary ambulatory care project using PEN-FAST scoring and oral challenges to improve antibiotic access and accuracy.

At MAD-ID 2025, Elizabeth Dodds Ashley, PharmD, MHS, explains how NHSN’s Antibiotic Resistance Option is shaping stewardship and clinical decision-making.

At MAD-ID, Timothy Aungst, PharmD, outlines the role of artificial intelligence in clinical decision-making, curriculum design, and infectious disease practice.

Ep 1, Part 2 of 4, insights from Robert Bransfield, MD's research on the immune system’s role in psychiatric disorders.

Following a positive safety review, Vaxart advances its needle-free, room-temperature stable oral vaccine candidate with government-backed funding and a year-long follow-up study.

Ep 1, Part 1 of 4: Robert Bransfield, MD, introduces his understanding of how infectious diseases may trigger or worsen psychiatric disorders through genetics, immune response, and environmental factors.

The state reported 3123 cases, a significant jump from 2024's 1011 cases in the same period, with experts citing environmental factors.

Jyothi N Purushotham, PhD, and Holly L Lutz, PhD, call for integrated immunological and ecological strategies to counter fast-evolving viral threats.

Alexander Laurenson presents T-cell-focused tool at the 2025 Vaccinology Conference using data from 18 countries and 748 HLA alleles to address immune diversity in Africa.

New meta-analysis at the 2025 vaccinology conference highlights the efficacy of maternal RSV vaccines, with calls for enhanced monitoring following safety issues with one candidate

SOF/VEL cured 98.9% of 7,027 hepatitis C cases globally, and peptide-decorated liposomes improved antifungal delivery against Candida species, and more

More than 80% of adults support COVID-19 vaccination, but hesitancy linked to side effects, geopolitics, and misinformation remains a challenge, says lead researcher Mahmud Sheku, MPH, MSc.

Zandraetta Tims-Cook, MD, MPH, highlights the need for inclusive HIV prevention strategies and discusses the potential of long-acting injectable PrEP in improving care and reducing disparities.

Posaconazole-loaded liposomes decorated with penetratin show up to 1300 times increased efficacy against biofilm formation and reduce fungal burden by 60% in murine models.

As therapies that impact the immune system become more common, patients are living longer but with increased susceptibility to infections, including viral, bacterial, fungal, and emerging diseases.

Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.

Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.

Paul Feuerstadt, MD, discusses the safe and effective use of RBL in preventing C difficile recurrence with positive physician feedback and high patient benefit